Regenxbio (NASDAQ:RGNX) Downgraded to “Sell” at BidaskClub

BidaskClub lowered shares of Regenxbio (NASDAQ:RGNX) from a hold rating to a sell rating in a research note released on Thursday morning, BidAskClub reports.

A number of other brokerages have also recently weighed in on RGNX. ValuEngine cut shares of Yext from a strong-buy rating to a buy rating in a report on Friday, May 10th. TheStreet cut shares of Trade Desk from a b- rating to a c- rating in a report on Thursday, May 9th. Raymond James began coverage on shares of Adverum Biotechnologies in a report on Thursday, June 13th. They issued a market perform rating for the company. Chardan Capital restated a buy rating and issued a $150.00 price objective (up previously from $145.00) on shares of Regenxbio in a report on Tuesday, June 18th. Finally, Zacks Investment Research cut shares of Zynerba Pharmaceuticals from a buy rating to a hold rating in a report on Saturday, May 11th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Regenxbio currently has an average rating of Hold and an average target price of $81.53.

Shares of RGNX traded up $0.93 during trading on Thursday, reaching $46.89. 7,546 shares of the company traded hands, compared to its average volume of 538,862. Regenxbio has a twelve month low of $38.56 and a twelve month high of $83.45. The firm has a market cap of $1.68 billion, a PE ratio of 19.78 and a beta of 0.71. The business’s 50-day moving average is $48.10. The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.21 and a current ratio of 14.21.

Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.04). Regenxbio had a negative net margin of 41.99% and a negative return on equity of 9.90%. The company had revenue of $0.88 million for the quarter. Sell-side analysts predict that Regenxbio will post -2.46 EPS for the current fiscal year.

In other Regenxbio news, SVP Curran Simpson sold 18,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $50.00, for a total transaction of $900,000.00. Following the completion of the transaction, the senior vice president now owns 57,500 shares in the company, valued at approximately $2,875,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kenneth T. Mills sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 19th. The stock was sold at an average price of $52.54, for a total transaction of $788,100.00. Following the transaction, the insider now owns 261,000 shares of the company’s stock, valued at approximately $13,712,940. The disclosure for this sale can be found here. Insiders have sold a total of 75,000 shares of company stock valued at $3,725,970 in the last quarter. 13.80% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Oregon Public Employees Retirement Fund lifted its position in shares of Regenxbio by 1.8% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 11,660 shares of the biotechnology company’s stock worth $668,000 after buying an additional 211 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its position in Regenxbio by 2.1% in the 4th quarter. Los Angeles Capital Management & Equity Research Inc. now owns 11,192 shares of the biotechnology company’s stock valued at $470,000 after purchasing an additional 225 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Regenxbio by 9.5% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,594 shares of the biotechnology company’s stock worth $149,000 after buying an additional 225 shares during the last quarter. State of Alaska Department of Revenue raised its position in Regenxbio by 2.4% during the 1st quarter. State of Alaska Department of Revenue now owns 10,310 shares of the biotechnology company’s stock worth $590,000 after buying an additional 245 shares during the last quarter. Finally, Mckinley Capital Management LLC Delaware raised its position in Regenxbio by 51.8% during the 1st quarter. Mckinley Capital Management LLC Delaware now owns 888 shares of the biotechnology company’s stock worth $51,000 after buying an additional 303 shares during the last quarter. Institutional investors own 81.48% of the company’s stock.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

See Also: Find a Trading Strategy That Works

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.